Lista de obras -

(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.

artículo científico publicado en 2013

A case of merkel leptomeningeal evolution after complete remission upon anti-PD-1 treatment

scientific article published on 11 April 2019

Acute interstitial nephritis related to immune checkpoint inhibitors.

artículo científico publicado en 2016

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.

artículo científico publicado en 2015

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

artículo científico publicado en 2017

Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients

artículo científico publicado en 2019

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

scientific article published on 01 December 2018

BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.

artículo científico publicado en 2017

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

artículo científico publicado en 2018

Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.

artículo científico publicado en 2014

CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.

artículo científico publicado en 2012

Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma

scientific article published on 15 August 2018

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy

artículo científico publicado en 2018

Communicating information to the general practitioner: the example of vemurafenib for metastatic melanoma

scientific article published on 11 November 2015

Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.

artículo científico publicado en 2018

Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy

artículo científico publicado en 2017

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

artículo científico

Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients

artículo científico publicado en 2019

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

artículo científico publicado en 2017

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

artículo científico publicado en 2016

Does needle biopsy cause an increased risk of extracapsular extension in the diagnosis of metastatic lymph node in melanoma?

artículo científico publicado en 2018

Double-positive CD4/CD8 mycosis fungoides: a rarely reported immunohistochemical profile.

artículo científico publicado en 2013

Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy

artículo científico publicado en 2019

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

artículo científico publicado en 2018

Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.

artículo científico publicado en 2017

Enzalutamide induced acute generalized exanthematous pustulosis.

artículo científico publicado en 2016

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

artículo científico publicado en 2019

Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation.

artículo científico publicado en 2014

High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study

artículo científico publicado en 2014

Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

artículo científico publicado en 2016

Incidence and risk factors for treatment failure with infliximab in psoriasis.

artículo científico publicado en 2013

Outbreak of contact sensitization to methylisothiazolinone: an analysis of French data from the REVIDAL-GERDA network

artículo científico publicado en 2014

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect

artículo científico publicado en 2017

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.

artículo científico

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

artículo científico publicado en 2019

Staging of primary cutaneous follicle centre B-cell lymphoma: bone marrow biopsy, CD10, BCL2 and t(14;18) are not relevant prognostic factors

scientific article published on 17 April 2019

Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study.

artículo científico publicado en 2016

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

artículo científico publicado en 2017

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

artículo científico publicado en 2018

The TNF Paradox in Cancer Progression and Immunotherapy

scientific article published on 31 July 2019

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.

artículo científico publicado en 2015

Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab

artículo científico publicado en 2016

Vemurafenib significantly decreases glomerular filtration rate.

artículo científico publicado en 2013

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

artículo científico publicado en 2017

[An unusual mediastinal mass].

artículo científico publicado en 2013

[Anti-TNFα antibodies in melanoma immunotherapy]

artículo científico publicado en 2018

[Dermatologic toxicities of immune checkpoint inhibitors]

artículo científico publicado en 2018

[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].

artículo científico publicado en 2016

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]

scientific article published on 13 September 2018

[Treatment of patients with brain metastases from a melanoma]

artículo científico publicado en 2019

[What's new in oncodermatology in 2015?]

artículo científico publicado en 2015

Lista de obras de

(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.

A case of merkel leptomeningeal evolution after complete remission upon anti-PD-1 treatment

Acute interstitial nephritis related to immune checkpoint inhibitors.

Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients.

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.

CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans.

Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy

Communicating information to the general practitioner: the example of vemurafenib for metastatic melanoma

Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.

Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Cutaneous Squamous Cell Carcinoma Tumour Size is Associated with Sentinel Lymph Node Metastasis in a Cohort of 69 Patients

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

Does needle biopsy cause an increased risk of extracapsular extension in the diagnosis of metastatic lymph node in melanoma?

Double-positive CD4/CD8 mycosis fungoides: a rarely reported immunohistochemical profile.

Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.

Enzalutamide induced acute generalized exanthematous pustulosis.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation.

High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study

Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

Incidence and risk factors for treatment failure with infliximab in psoriasis.

Outbreak of contact sensitization to methylisothiazolinone: an analysis of French data from the REVIDAL-GERDA network

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma

Staging of primary cutaneous follicle centre B-cell lymphoma: bone marrow biopsy, CD10, BCL2 and t(14;18) are not relevant prognostic factors

Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas

The TNF Paradox in Cancer Progression and Immunotherapy

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.

Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab

Vemurafenib significantly decreases glomerular filtration rate.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

[An unusual mediastinal mass].

[Anti-TNFα antibodies in melanoma immunotherapy]

[Dermatologic toxicities of immune checkpoint inhibitors]

[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]

[Treatment of patients with brain metastases from a melanoma]

[What's new in oncodermatology in 2015?]